PMID- 22854010
OWN - NLM
STAT- MEDLINE
DCOM- 20130506
LR  - 20171116
IS  - 1952-4013 (Electronic)
IS  - 1167-1122 (Linking)
VI  - 22
IP  - 5
DP  - 2012 Sep-Oct
TI  - Human beta-defensin-2 and psoriasin, two new innate immunity targets of zinc 
      gluconate.
PG  - 634-9
LID - 10.1684/ejd.2012.1800 [doi]
AB  - BACKGROUND: Antimicrobial peptides (AMPs) are a large family of peptides 
      implicated in innate immunity, especially in the epidermis. Zinc gluconate has 
      been proven to be efficient to treat inflammatory dermatoses, such as acne 
      vulgaris. OBJECTIVES: The aim of our work was to determine whether AMPs could be 
      new targets of zinc gluconate treatment in inflammatory dermatoses. MATERIAL AND 
      METHODS: To test this hypothesis, we used an ex vivo lipopolysaccharide 
      (LPS)-induced inflammatory skin explant model, with or without zinc gluconate 
      pretreatment. We evaluated human beta-defensin-2 (hBD-2), human beta-defensin-4 (hBD-4) 
      and psoriasin protein expression and release by immunohistochemistry and ELISA, 
      as well as the mRNA expression level by quantitative PCR. RESULTS: We found that 
      hBD-2 and psoriasin mRNA expression levels and hBD-2 extracellular release, but 
      not hBD-4 expression and release, were significantly upregulated by zinc 
      gluconate in LPS-stimulated inflammatory skin explants. CONCLUSION: These results 
      suggest that hBD-2 and psoriasin may be two main targets of zinc gluconate, 
      involved in its anti-inflammatory activity in dermatoses.
FAU - Poiraud, Carole
AU  - Poiraud C
AD  - Inserm U892, Department of Dermato-Oncology Nantes University Hospital, 1 Place 
      Alexis-Ricordeau, 44093 Nantes, France.
FAU - Quereux, Gaelle
AU  - Quereux G
FAU - Knol, Anne-Chantal
AU  - Knol AC
FAU - Zuliani, Thomas
AU  - Zuliani T
FAU - Allix, Remy
AU  - Allix R
FAU - Khammari, Amir
AU  - Khammari A
FAU - Dreno, Brigitte
AU  - Dreno B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Eur J Dermatol
JT  - European journal of dermatology : EJD
JID - 9206420
RN  - 0 (DEFB4A protein, human)
RN  - 0 (Gluconates)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (RNA, Messenger)
RN  - 0 (S100 Calcium Binding Protein A7)
RN  - 0 (S100 Proteins)
RN  - 0 (S100A7 protein, human)
RN  - 0 (beta-Defensins)
RN  - R4R8J0Q44B (gluconic acid)
SB  - IM
MH  - Gene Expression/drug effects
MH  - Gluconates/*pharmacology
MH  - Humans
MH  - In Vitro Techniques
MH  - Lipopolysaccharides/pharmacology
MH  - RNA, Messenger/metabolism
MH  - S100 Calcium Binding Protein A7
MH  - S100 Proteins/genetics/*metabolism
MH  - Skin/drug effects/*metabolism
MH  - Statistics, Nonparametric
MH  - Up-Regulation/*drug effects
MH  - beta-Defensins/genetics/*metabolism
EDAT- 2012/08/03 06:00
MHDA- 2013/05/07 06:00
CRDT- 2012/08/03 06:00
PHST- 2012/08/03 06:00 [entrez]
PHST- 2012/08/03 06:00 [pubmed]
PHST- 2013/05/07 06:00 [medline]
AID - ejd.2012.1800 [pii]
AID - 10.1684/ejd.2012.1800 [doi]
PST - ppublish
SO  - Eur J Dermatol. 2012 Sep-Oct;22(5):634-9. doi: 10.1684/ejd.2012.1800.